Retrospective Study of Quetiapine in Children and Adolescents with Pervasive Developmental Disorders

  • Antonio Y. Hardan
  • Roger J. Jou
  • Benjamin L. Handen


A retrospective study was conducted in a clinic specialized in treating individuals with developmental disabilities to examine the effectiveness and tolerability of quetiapine in children and adolescents with pervasive developmental disorders. Ten consecutive outpatients (age = 12.0 ± 5.1 years) treated with quetiapine (dose = 477 ± 212 mg, duration = 22.0 ± 10.1 weeks) were identified and six were judged to be responders based on impressions from chart review and Conners Parent Scale (CPS). Improvements were observed in the conduct, inattention, and hyperactivity subscales of the CPS. Adverse events were mild with sedation being the most common, and no patient required treatment termination. Quetiapine may be beneficial in children and adolescents with pervasive developmental disorders, however open-label and double-blind, placebo-controlled studies are warranted.


Quetiapine antipsychotic agents autism pervasive developmental disorder children adolescents 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adityanee, A. M., Schulz, S. C. 2002Clinical use of quetiapine in disease states other than schizophreniaJournal of Clinical Psychiatry633238Google Scholar
  2. Arvanitis, L. A., Miller, B. G. 1997Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placeboThe Seroquel Trial 13 Study Group. Biological Psychiatry42233246Google Scholar
  3. David, S. R., Taylor, C. C., Kinon, B. J., Breier, A. 2000The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophreniaClinical Therapeutics2210851096Google Scholar
  4. Findling, R. L. 2002Use of quetiapine in children and adolescentsJournal of Clinical Psychiatry632731Google Scholar
  5. Goyette, C. H., Conners, C. K., Ulrich, R. F 1978Normative data on revised Conners Parent and Teacher Rating ScalesJournal of Abnormal Child Psychology6221236Google Scholar
  6. Guy W., (1976). ECDEU Assessment Manual of Psychopharmacology. Rockville, MD: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research ProgramsGoogle Scholar
  7. Kleinberg, D. L., Davis, J. M., Coster, R., Baelen, B., Brecher, M. 1999Prolactin levels and adverse events in patients treated with risperidoneJournal of Clinical Psychopharmacology195761Google Scholar
  8. Malone, R. P., Ernst, M., Godfrey, K. A., Locascio, J. J., Campbell, M. 1991Repeated episodes of neuroleptic-related dyskinesias in autistic childrenPsychopharmacology Bulletin27113117Google Scholar
  9. Martin, A., Koenig, K., Scahill, L., Bregman, J. 1999Open-label quetiapine in the treatment of children and adolescents with autistic disorderJournal of Child Adolescent Psychopharmacology999107Google Scholar
  10. McConville, B. J., Arvanitis, L. A., Thyrum, P. T., Yeh, C., Wilkinson, L. A., Chaney, R. O.,  et al. 2000Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disordersJournal of Clinical Psychiatry61252260Google Scholar
  11. Research Units on Pediatric Psychopharmacology Autism Network2002Risperidone in children with autism and serious behavioral problemsNew England Journal of Medicine347314321Google Scholar
  12. Sadock, B. J., Sadock, V. A., Kaplan, H. I. 2001Kaplan & Sadock’s pocket handbook of clinical psychiatry (3rd ed.)Lippincott Williams & WilkinsPhiladelphiaGoogle Scholar
  13. Shaw, J. A., Lewis, J. E., Pascal, S., Sharma, R. K., Rodriguez, R. A., Guillen, R.,  et al. 2001A study of quetiapine: Efficacy and tolerability in psychotic adolescentsJournal of Child Adolescent Psychopharmacology11415424Google Scholar
  14. Taylor, D. M., McAskill, R. 2000Atypical antipsychotics and weight gain – a systematic reviewActa Psychiatrica Scandinavica101416432Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  • Antonio Y. Hardan
    • 1
    • 3
  • Roger J. Jou
    • 2
  • Benjamin L. Handen
    • 1
  1. 1.Western Psychiatric Institute and ClinicUniversity of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Department of PsychiatryYale University School of MedicineNew HauehUSA
  3. 3.Western Psychiatric Institute and ClinicUniversity of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations